Sponsored by Iridex Corporation
The VariLiteTM for Fundamental Cosmetic Applications
For many patients and some clinicians, the notion of treating “vascular lesions” typically calls to mind red telangiectases, diffuse erythema, and deeper red vessels. Yet, for a number of patients, visible blue vessels can be just as troubling as red ones. Until recently, the only laser that provided any possible utility for the treatment of blue vessels or purpura was the 1064nm Nd:YAG laser. However, treatment was associated with a significant incidence of pitting. The 940nm wavelength— available in the VariLite (532nm KTP/940nm diode laser, IRIDEX)—efficiently targets blue vessels with a significantly decreased incidence of pitting.
Meeting Patient Demand
The combination of the 532nm and 940nm wavelength in one machine allows the clinician to treat a sizable proportion of cosmetic dermatology patients. The clinical reality is that a majority of patients present to the dermatologist for treatment of both red and blue vessels, lentigines and freckles, diffuse erythema, and dyschromia. Treatment for these common presentations can now be provided with a single laser. VariLite is unique in the combination of wavelengths the system offers and, therefore, the diversity of vessels and vascular and pigmented lesions it targets.
Treatment with the VariLite is associated with a significant level of patient comfort. Patients do not experience pain or notable discomfort during treatment, which can take as little as five minutes for discrete vessels. There is no downtime following treatment. Patients should expect to undergo three treatments, provided about a month apart. Vessels have a tendency to return, so patients should also anticipate maintenance treatments at intervals (up to a year apart).
Meeting Clinicians’ Needs
In addition to its versatility of applications, the VariLite offers remarkable convenience for a practice. A variety of handpieces and spot sizes are available. The device is small and lightweight, allowing it to be moved easily from room to room or even from one practice location to another.
The system is easy to use, with no difficulty associated with swapping handpieces or changing spot sizes. Other modular systems offer different wavelengths, but switching from one wavelength to another can be a challenge. With the VariLite, changing from one wavelength to another can literally be done with one hand.
A Foundational System
By combining into a single system the ability to treat both red and blue vessels, and pigmented lesions, VariLite enables a clinician to treat a very wide range of fundamental cosmetic concerns. As such, the 532nm KTP/940nm diode laser may represent a reasonable option for a clinician just starting out in cosmetic laser surgery. The VariLite will not provide improvement in skin texture and wrinkling, however, treatment pairs nicely with other popular cosmetic procedures, such as fillers and botulinum toxins. These additional cosmetic services can be provided in the same visit. The VariLite can provide a basis for building a cosmetic practice with ample opportunity to incorporate additional complementary laser systems, such as one of the many that target texture, as demand grows. The VariLite is an affordable system that offers ample opportunity to make a return on the investment. It meets the demands of cosmetic patients and needs of busy clinicians.
“One of the great thingsabout being in the laser field isthere are new lasers that come outevery day. It makes it a very excitingarena to be in. The problem is the popularmachine of today, unfortunately,often becomes the machine that youdon't need a year from now. The VariLiteis tried and true. The wavelengths—532nanometers, 940 nanometers—theywork. We've had the machine for severalyears. It doesn't break down.Patients send their friends. It's agreat machine to have in theoffice.”
TOP 5 ARTICLES FROM 2010
- Technology Connection: EMR Meets Modern Technology
Touch-screen technology may offer multiple benefits for adoption and effective use of EMRs.
By Michael Sherling, MD
- Recent Developments: What’s Next for the Dermatology Pharmaceutical Industry?
No doubt the dermatology pharmaceutical industry is undergoing a change. But what does it mean?
- Dermatology Q&A: New Directions in the Treatment of Hypopigmented Scars
A new study shows that off-label use of an unexpected agent yields promising results in the repigmentation of hypopigmented scars.
By Ted Pigeon, Senior Associate Editor
- Epidermal Barrier Dysfunction: Beyond Atopic Dermatitis
Specialists describe how a disrupted barrier contributes to common dermatoses and offer strategies for treatment.
By Joseph Bikowski, MD and Matthew Zirwas, MD
- Therapeutics Update